Navigation Links
AMDL, Inc. New President & CEO Douglas MacLellan to Present at Rodman & Renshaw Annual Global Investment Conference November 12, 2008
Date:11/6/2008

TUSTIN, Calif., Nov. 6 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc. (Amex: ADL), a leading vertically-integrated pharmaceutical company with major operations in China and the U.S., today announced its newly appointed Chairman and CEO Mr. Douglas MacLellan will present at Rodman & Renshaw's Annual Global Investment Conference taking place on Wednesday, November 12th, 2008 at the New York Palace Hotel in New York City.

Mr. MacLellan will provide an informative overview of AMDL's core business and growth strategy for its China specialty pharmaceuticals, in-vitro diagnostics and cancer therapeutic divisions. The Company has an aggressive and focused approach to capitalize on these three market sectors, positioning AMDL as one of most rapidly growing and highly-opportunistic micro-cap investment prospects in the vertically-integrated, specialty pharmaceutical sector.

In 2008 alone, AMDL met numerous operational milestones which include: securing more than $25 million in sales contracts for its best-selling HPE anti-aging product line; expanding AMDL's overall revenue opportunity for HPE by launching additional HPE product formulations; and successfully securing US FDA clearance for AMDL's ELISA DR-70(R) FDP cancer diagnostic test. The ELISA DR-70(R) FDP cancer diagnostic test is the first test to be cleared by the US FDA in over 25 years for the monitoring of colorectal cancer.

Attendees wishing to learn more about the Company can attend Mr. MacLellan's presentation which is scheduled at 9:55 a.m. EST in the Henry Salon, 5th Floor of the New York Palace Hotel. Additionally, interested investors can visit the Company's corporate website at http://www.amdl.com or contact AMDL's investor relations department at 206.310.5323.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 400 people in the U.S. and China. The Company has an additional 4 pharmaceutical and diagnostic products under review by various regulatory authorities.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL, Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties related to the Company's access to additional capital, competition and dependence on key management.

AMDL Contact:

Kristine Szarkowitz

Director-Investor Relations

kszarkowitz@amdl.com

(206) 310-5323


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team
2. AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO
3. AMDL, Inc.s President & CEO Mr. Gary Dreher Retires
4. AMDL, Inc. Named to Deloitte LLC Technology Fast 50
5. AMDL, Inc. Announces Strategic Realignment
6. AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008
7. AMDL, Inc. Closes Private Placement of Convertible Notes
8. The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue
9. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
10. AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
11. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... According to a new market research report "Oligonucleotide Synthesis Market ... (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, Pharmaceutical, ... is expected to reach USD 2.20 Billion by 2021 from USD ... forecast period. Continue Reading ... ...
(Date:12/8/2016)... ... December 08, 2016 , ... From wearable devices ... taking over sports. On Thursday, December 15th a panel of entrepreneurs, innovators and ... playing field at a Smart Talk session. Smart Talk will run from 8:30 ...
(Date:12/8/2016)... BELLINGHAM, Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... neural circuits with very high precision light to control cells — optogenetics — ... brain. In the current state of the art, spatially patterned light projected via ...
(Date:12/8/2016)... ... 2016 , ... KBioBox llc announced today the launch of ... a sophisticated “3 click” gene dditing off target analysis program and a “3 ... https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. Scientists, pharmaceutical researchers ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
(Date:12/6/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, and the Prison Entrepreneurship ... year funding commitment by Securus to PEP and ... reentry support to more inmates and their families. ... Prison Entrepreneurship Program (PEP) is an independent 501(c)(3) ...
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):